<DOC>
	<DOCNO>NCT00669292</DOCNO>
	<brief_summary>This single institution phase I / II trial evaluate safety efficacy URLC10-177 TTK-567 emulsify Montanide ISA 51 combination different dos CpG7909 patient advance recurrent esophageal cancer .</brief_summary>
	<brief_title>PhaseⅠ/Ⅱ Study URLC10-177 TTK-567 Peptide Vaccine Combined With CpG7909 Patients With Esophageal Cancer</brief_title>
	<detailed_description>phase I : Patients vaccinate day 1,8,15 22 28-day treatment cycle . On vaccination day , URLC10-117 peptide ( 1mg ) TTK-567 peptide ( 1mg ) mix CpG 7909 ( escalate dos : 0 , 0.02 , 0.1mg/kg ) emulsify Montanide ISA 51 administer subcutaneous injection . Repeated cycle vaccine administer patient develop progressive disease unacceptable toxicity , maximum 2 cycle , whichever occur first . In phase I study , evaluate safety tolerability URLC10-177 , TTK-567 different dos CpG7909 determine recommend phase II dose CpG7909 . phase II : Patients vaccinate day 1,8,15 22 28-day treatment cycle . On vaccination day , URLC10-117 peptide ( 1mg ) TTK-567 peptide ( 1mg ) mix CpG 7909 ( recommend dose determined phase I study ) emulsify Montanide ISA 51 administer subcutaneous injection . Repeated cycle vaccine administer 2 cycle . In phase II study , evaluate efficacy vaccine therapy .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS 1. locally advanced metastatic esophageal cancer preclude curative surgical resection recurrent esophageal cancer 2. measurable disease CT scan PATIENT CHARACTERISTICS 1 . ECOG performance status 01 2 . Life expectancy &gt; 3 month 3 . Laboratory value follow 2000/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 75000/mm3 Aspartate transaminase &lt; 150 IU/L Alanine transaminase &lt; 150 IU/L Creatinine &lt; 2.0 mg/dl 4 . HLAA*2402 5 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Active uncontrolled infection 4 . Concurrent treatment steroid immunosuppressing agent 5 . Prior chemotherapy , radiation therapy , immunotherapy within 4 week 6 . Clinically significant heart disease 7 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>peptide</keyword>
	<keyword>URLC10</keyword>
	<keyword>TTK</keyword>
	<keyword>CpG7909</keyword>
</DOC>